120378-17-8

Basic information

• Product Name: 2-[(tert-butoxycarbonyl)amino]-4-phenylbutanoic acid
• Synonyms: 2-[(tert-butoxycarbonyl)amino]-4-phenylbutanoic acid;BOC D,L-HOMOPHENYLALANINE;b-(Boc-amino)-benzenebutanoic acid;Benzenebutanoicacid,-[[(1,1-dimethylethoxy)carbonyl]amino]-
• CAS NO: 120378-17-8
• Molecular Formula: C₁₅H₂₁NO₄
• Molecular Weight: 279.33154
• Mol File: 120378-17-8.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 2-[(tert-butoxycarbonyl)amino]-4-phenylbutanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[(tert-butoxycarbonyl)amino]-4-phenylbutanoic acid(120378-17-8)
• EPA Substance Registry System: 2-[(tert-butoxycarbonyl)amino]-4-phenylbutanoic acid(120378-17-8)

Safety Data

• Hazardous Substances Data: 120378-17-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2-[(tert-butoxycarbonyl)amino]-4-phenylbutanoic acid is used as a building block in organic synthesis for the preparation of peptide-based drugs and pharmaceuticals. Its Boc protecting group allows for selective reactions and controlled synthesis of complex organic molecules.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 2-[(tert-butoxycarbonyl)amino]-4-phenylbutanoic acid is utilized as a key component in the development of new drugs. Its unique structure and reactivity contribute to the design and synthesis of innovative therapeutic agents.
Used in Peptide Research:
2-[(tert-butoxycarbonyl)amino]-4-phenylbutanoic acid is employed in the study of peptide structure and function. Its incorporation into peptides allows researchers to investigate the effects of structural modifications on peptide properties and biological activities.
Used in Material Science:
In the field of material science, 2-[(tert-butoxycarbonyl)amino]-4-phenylbutanoic acid has potential applications due to its reactivity and ability to form various chemical bonds. It can be used to develop new materials with specific properties for various applications.
Used in Biochemistry:
2-[(tert-butoxycarbonyl)amino]-4-phenylbutanoic acid also has potential uses in biochemistry, where its unique structure and reactivity can be exploited for the study of enzyme mechanisms, protein interactions, and other biochemical processes.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 131270-08-1 (R)-3-amino-4-phenylbutanoic acid 
• 15099-85-1 3(S)-amino-4-phenylbutyric acid 

Downstream Products

• 877374-07-7 1-(3-tert-butoxycarbonylamino-4-phenylbutyryl)-pyrrolidin-2-carbonic acid methyl ester 
• 1391423-36-1 tert-butyl 4-amino-1-phenylbutan-2-ylcarbamate 
• 845267-74-5 DL-6-benzylpiperidine-2,4-dione 

Relevant articles and documents

ISOQUINOLINOPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS

Heteroarylpyridinone derivatives represented by formula (I) wherein R1, R2, R3, R4, R5, and X are as defined in the specification, compositions thereof, and methods of use thereof. Particularly, there are described isoquinolinoyrrolopyridinones, pharmaceutical compositions comprising them and their use as therapeutic agents in the treatment of cancer and cell proliferation disorders.

N-substituted pyrrolopyridinones active as kinase inhibitors

Compounds represented by formula (I) wherein A, R1, R2, R3, R4, R5, and R6 are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.

Novel compounds that inhibit dipeptidyl peptidase (DPP-IV) and neprilysin (NEP) and/or angiotensin converting enzyme (ACE)

This invention relates to novel compounds, compositions containing the compounds, that inhibit dipeptidyl peptidase (especially DPP-IV) and neprilysin (NEP, neutral endopeptidase) as well as dipeptidyl peptidase (especially DPP-IV) and angiotensin converting enzyme (ACE) and/or dipeptidyl Peptidase (especially DPP-IV) and vasopeptidases (especially ACE and NEP). These compounds and pharmaceutical compositions thereof are useful for the treatment as well as the prevention of type 2 diabetes mellitus.

PYRIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS

Pyridylpyrrole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treat

PYRIMIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS

Pyrimidylpyrrole derivatives of formula (1) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be

Process for producing threo-3-amino-2-hydroxybutanoyl-aminoacetic acids, as well as novel intermediated therefor and process for producing them

A process for producing threo-3-amino-2-hydroxybutanoylaminoacetic acids comprises the steps of allowing to react a starting compound represented by the general formula: STR1 wherein R1 represents a naphthyl or a group of the formula: STR2 in which R6 and R7 represent individually hydrogen, halogen, amino or a protected amino, hydroxy or a protected hydroxy, a lower alkoxy or a lower alkyl and R2 represents a protected amino, with a starting compound represented by the general formula: STR3 wherein R3 represents hydrogen or an ester residue, to obtain threo-3-protected amino-2-hydroxy-4-oxobutanoic acid or its ester represented by the general formula: STR4 wherein R1, R2 and R3 have the same meanings as above, and then reducing the same into threo-3-protected amino-2-hydroxybutanoic acid or its ester represented by the general formula: STR5 wherein R1, R2 and R3 have the same meanings as above, and further converting the above compound into 3-amino-2-hydroxybutanoic acid represented by the general formula: STR6 wherein R2 ' represents amino or a protected amino, thereafter condensing the same, in a conventional manner for forming a peptide coupling, with a compound represented by the general formula: STR7 wherein R4 represents an alkyl having 3-4 carbon atom or 3-guanidinopropyl, while previously protecting as required those groups not relevant to the reaction, and removing the protecting groups for the functional groups to produce threo-3-amino-2-hydroxybutanoylaminoacetic acids represented by the general formula: STR8 wherein R1 and R4 have the same meanings as above. This invention also provides the compounds represented by the general formula (III) as novel intermediates for the above aimed compounds and a process for producing the intermediates.